Received: 16.05.2025 Accepted: 17.12.2025 Published online: 29.12.2025
УДК: 616.379-008.64-085
DOI: 10.53511/pharmkaz.2025.6.1
EXPERIENCE OF USING ISTA IN CLINICAL PRACTICE (INTERIM RESULTS)
Imangali A.S.²,¹, Alipova A.T.¹, Zhummanova B.M.¹,
Unerbayeva S.A.², Bolshakova S.V.¹, Abueva A.K.¹
¹Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan
²Asfendiyarov Clinic of Internal Diseases, Almaty, Republic of Kazakhstan
Introduction. Sitagliptin (Ista) plays a significant role in the management of type 2 diabetes mellitus due to its incretin-based mechanism and favorable safety profile. However, real-world data on its use in Kazakhstan remain limited. This study presents preliminary findings from an interim analysis of Ista use in outpatient clinical practice
Materials and Methods. The study included 43 patients with a verified diagnosis of T2DM combined with overweight and obesity. The mean age of the patients was 58.7±7.74 years, and the disease duration was 7.44±5.20 years. All patients received Ista at a dose of 100 mg orally once daily, either as monotherapy or in combination therapy. Assessments were conducted at baseline and after 3 months of therapy. The first group 7 included 11 patients receiving Ista 100 mg/day as monotherapy. The second group consisted of 28 patients taking Ista 100 mg in combination with biguanides, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and basal insulin. At baseline and after 3 months of therapy, glycated hemoglobin (HbA1c) levels, body weight, body mass index (BMI), waist circumference (WC), visceral fat level, and lipid profile parameters, including
total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides, were assessed.
Results and Discussion. Based on the interim analysis of clinical and laboratory data, after 12 weeks of therapy, patients with type 2 diabetes mellitus (T2DM) showed a statistically significant improvement in body weight and visceral fat reduction, as well as a tendency toward normalization of laboratory parameters. The HbA1c level decreased by an average of 13% in the first group (p < 0.051706) and by 10.7% in the second group (p < 0.01). Body weight decreased by 2% (p < 0.00034) in the first group and by 2.4% (p < 0.000909) in the second group. Visceral fat was reduced by 10% in both groups, with p < 0.089 in the first group and p <0.00004 in the second group. All 43 patients tolerated the therapy well, and no adverse events were recorded
during the treatment period.
Conclusion.The interim finding of the study indicate that Ista (Sitagliptin) is effective in the treatment of T2DM. Combination therapy with Sitagliptin and other oral antidiabetic drugs (OADs) was associated with a more substantial reduction in glycemic levels and visceral fat.
Keywords: type 2 diabetes mellitus, visceral fat, incretins, DPP-4 inhibitors, Sitagliptin, Ista, TECOS.
